Alterations of these genes were not detected in the patients classed as partial responders, whereas 8/14 patients classed as non-responders had tumours with deep deletion or pathogenic mutation of TP53 and CDKN1B (p27; Supplementary Table 6). This evidence concerns the gene CDKN1B and neoplasm.